Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study

To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2018-11, Vol.14 (27), p.2861-2874
Main Authors: Hochmair, Maximilian J, Morabito, Alessandro, Hao, Desiree, Yang, Cheng-Ta, Soo, Ross A, Yang, James C-H, Gucalp, Rasim, Halmos, Balazs, Wang, Lara, Golembesky, Amanda, Märten, Angela, Cufer, Tanja
Format: Article
Language:English
Subjects:
Acrylamides
Adult
Afatinib - pharmacology
Afatinib - therapeutic use
Aged
Aged, 80 and over
Aniline Compounds
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer therapies
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - pathology
Chemotherapy
Clinical medicine
Drug dosages
Drug Resistance, Neoplasm - genetics
Electronic health records
Epidermal growth factor
ErbB Receptors - genetics
Ethnicity
Feasibility Studies
Female
Humans
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Male
Metastasis
Middle Aged
Mutation
Observational studies
Patients
Piperazines - pharmacology
Piperazines - therapeutic use
Protein Kinase Inhibitors - pharmacology
Protein Kinase Inhibitors - therapeutic use
Retrospective Studies
Survival Analysis
Targeted cancer therapy
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months prior to data entry. Primary outcome was time on treatment. Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. NCT03370770.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2018-0711